Risk factors for treatment failure in scabies: a cohort study

被引:31
|
作者
Aussy, A. [1 ,2 ]
Houivet, E. [3 ,4 ]
Hebert, V. [1 ,2 ]
Colas-Cailleux, H. [1 ,2 ]
Laaengh, N. [1 ,2 ]
Richard, C. [1 ,2 ]
Ouvry, M. [1 ,2 ]
Boulard, C. [1 ,2 ]
Leger, S. [1 ,2 ]
Litrowski, N. [1 ,2 ]
Benichou, J. [3 ,4 ]
Joly, P. [1 ,2 ]
Bechu, S.
Mion-Mouton, N.
Lafaurie, O.
Barrel, A.
Pulluard, M.
Hamel, V.
Dore, M. X.
Duflo, E.
Lardans-Cassius, S.
Rzeznik, J. C.
Baricault, S.
机构
[1] Rouen Univ Hosp, Dept Dermatol, Rouen, France
[2] Univ Rouen Normandie, INSERM, U1234, Rouen, France
[3] Rouen Univ Hosp, Dept Biostat, Rouen, France
[4] Univ Rouen Normandie, INSERM, U1219, Rouen, France
关键词
ORAL IVERMECTIN; PREVALENCE; EPIDEMIOLOGY; CREAM;
D O I
10.1111/bjd.17348
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries. Objectives To identify predictors of treatment failure of scabies in ambulatory populations. Methods This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment. Results In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2 center dot 15, 95% confidence interval (CI) 1 center dot 22-3 center dot 77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10 center dot 2. 95% CI 4 center dot 49-23 center dot 2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4 center dot 31, 95% CI 1 center dot 89-9 center dot 84); (iv) absence of decontamination of furnishings (OR 8 center dot 72, 95% CI 3 center dot 50-21 center dot 8), in particular sofa and cushions (OR 5 center dot 90, 95% CI 2 center dot 34-14 center dot 9), mattresses (OR 4 center dot 16, 95% CI 1 center dot 35-12 center dot 8) or car seats (OR 6 center dot 57, 95% CI 3 center dot 27-13 center dot 2) and (v) absence of written documents explaining treatment modalities (OR 5 center dot 18, 95% CI 2 center dot 57-10 center dot 4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6 center dot 62, 95% CI 2 center dot 71-16 center dot 2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3 center dot 51, 95% CI 1 center dot 55-7 center dot 95) and (iii) absence of decontamination of furniture with acaricides (OR 5 center dot 81, 95% CI 1 center dot 96-16 center dot 7). Conclusions Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.
引用
收藏
页码:888 / 893
页数:6
相关论文
共 50 条
  • [1] Failure of scabies treatment: a systematic review and meta-analysis
    Mbuagbaw, Lawrence
    Sadeghirad, Behnam
    Morgan, Rebecca L.
    Mertz, Dominik
    Motaghi, Shahrzad
    Ghadimi, Maryam
    Babatunde, Ifeoluwa
    Zani, Babalwa
    Pasumarthi, Tejanth
    Derby, Mckenzie
    Kothapudi, Venkata N.
    Palmer, Nicole R.
    Aebischer, Anton
    Harder, Thomas
    Reichert, Felix
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (02) : 163 - 173
  • [2] Therapeutic failure in scabies : An observational study
    De Sainte Marie, B.
    Mallet, S.
    Gaudy-Marqueste, C.
    Baumstarck, K.
    Bentaleb, N.
    Loundou, A.
    Hesse, S.
    Monestier, S.
    Grob, J. -J.
    Richard, M. -A.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2016, 143 (01): : 9 - 15
  • [3] Exploring risk factors of short-term readmission in heart failure patients: A cohort study
    Niu, Xiao Na
    Wen, He
    Sun, Nan
    Zhao, Ran
    Wang, Ting
    Li, Yan
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [4] Psoriasis and risk of heart failure: a nationwide cohort study
    Khalid, Usman
    Ahlehoff, Ole
    Gislason, Gunnar Hilmar
    Kristensen, Soren Lund
    Skov, Lone
    Torp-Pedersen, Christian
    Hansen, Peter Riis
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (07) : 743 - 748
  • [5] Inherent and modifiable risk factors for peripheral venous catheter failure during cancer treatment: a prospective cohort study
    Larsen, Emily N.
    Marsh, Nicole
    O'Brien, Catherine
    Monteagle, Emily
    Friese, Christopher
    Rickard, Claire M.
    SUPPORTIVE CARE IN CANCER, 2021, 29 (03) : 1487 - 1496
  • [6] Risk factors for recurrence of scabies: A retrospective study of scabies patients in a long-term care hospital
    Makigami, Kuniko
    Ohtaki, Noriko
    Ishii, Norihisa
    Tamashiro, Tetsuko
    Yoshida, Sadao
    Yasumura, Seiji
    JOURNAL OF DERMATOLOGY, 2011, 38 (09) : 874 - 879
  • [7] Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study
    Koppikar, Sahil
    Colaco, Keith
    Harvey, Paula
    Akhtari, Shadi
    Chandran, Vinod
    Gladman, Dafna D.
    Cook, Richard
    Eder, Lihi
    ARTHRITIS CARE & RESEARCH, 2022, 74 (08) : 1244 - 1253
  • [8] The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors
    van der Ende, M. Yldau
    Hartman, Minke H. T.
    Hagemeijer, Yanick
    Meems, Laura M. G.
    de Vries, Hendrik Sierd
    Stolk, Ronald P.
    de Boer, Rudolf A.
    Sijtsma, Anna
    van der Meer, Peter
    Rienstra, Michiel
    van der Harst, Pim
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 228 : 495 - 500
  • [9] The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors
    Marques, Juliana R.
    Guecheva, Temenouga N.
    Pfeifer, Paula M.
    Vieira, Daniela R.
    Pellanda, Lucia C.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 277 : 247 - 247
  • [10] Risk factors for scabies in hospital: a systematic review
    Kim, Dong-Hee
    Kim, Yujin
    Yun, Sook Young
    Yu, Hak Sun
    Ko, Hyun-Chang
    Kim, MinWoo
    BMC INFECTIOUS DISEASES, 2024, 24 (01)